Our analysis yielded thousands of data points and unearthed two critically important trends that we think are widely misunderstood or unknown by the VC ecosystem, the limited partners in the asset class, and the media that covers it.
Despite the fact that these drugs have been on the market for more than two decades, like any class of drugs that are prescribed for chronic use, their effects over decades of use are unknown.